US/UK/Canada

Share

Contacts

  • Orexo
    Box 303 751 05 Uppsala
    +46 (0)18 780 88 00
    +46 (0)18 780 88 88
    http://www.orexo.com

    • Quotes

    With the acquisition of the rights to two digital health products from GAIA and the appointment of Dennis, a thought leader in the digital health industry in the US, we are well positioned to lead this development within the complementary disease areas of our pharmaceutical business.
    Nikolaj Sørensen, President and CEO
    Our strategy is to focus on solutions with scientifically proven therapeutic effect which will benefit the healthcare system as a whole and more importantly patients.
    Nikolaj Sørensen, CEO, about Digital Therapies
    I am convinced that DTx will become an integral and natural part of addiction treatment in the future. This digital therapy for OUD patients is perfectly positioned with Orexo’s competences and commercial organization in the US.
    Nikolaj Sørensen, President and CEO
    Mundipharma Australia has been a good partner in the approval process and we are confident that their experience and infrastructure will create a strong foundation for a successful launch of Zubsolv®
    Nikolaj Sørensen, President and CEO
    Pick a time period -
    Tags ( Active)

    Number of shares and votes in Orexo

    Uppsala, Sweden – February 28, 2019 – The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants in connection with the company’s incentive programs. Today, the last trading day of the month, there are in total 35,490,610 shares, whereof 34,600,610 are ordinary shares and 890,000 class C shares and 34,657,110 votes in the company. For further information, please contact: Orexo AB (publ.) Lena Wange, IR & Communications ManagerTel: +46 (0)18 780 88 00E-mail: ir@orexo.com About Orexo Orexo develops improved pharmaceuticals based on

    Number of shares and votes in Orexo

    Uppsala, Sweden – June 29, 2018 – The number of shares and votes in Orexo AB has changed as a result of the issue and repurchase of 325,000 class C shares as announced on June 15, 2018. Today, the last trading day of the month, there are in total 35,450,456 shares - whereof 34,560,456 are ordinary shares and 890 000 class C shares - and 34,649,456 votes in the company. For further information, please contact: Orexo AB (publ.) Henrik Juuel, EVP and Lena Wange, IR & Communications ManagerCFO                   Tel: +46 (0)18 780 88 Tel: +46 (0)18 780 88 0000E-mail:

    Number of shares and votes in Orexo

    Uppsala, Sweden – January 31, 2018 – The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants in connection with the company’s incentive programs. Today, the last trading day of the month, there are in total 35,125,456 shares, whereof 34,560,456 are ordinary shares and 565,000 class C shares and 34,616,956 votes in the company. For further information, please contact: Orexo AB (publ.) Henrik Juuel, EVP and CFO Lena Wange, IR & Communications ManagerTel: +46 (0)18 780 88 00 Tel: +46 (0)18 780 88 00E-mail: ir@orexo.com E-

    Number of shares and votes in Orexo

    Uppsala, Sweden – June 30, 2017 – The number of shares and votes in Orexo AB has changed as a result of the issue and repurchase of class C shares as announced on June 16, 2017. Today, the last trading day of the month, there are in total 35 104 585 shares - whereof 34,539,585 are ordinary shares and 565 000 class C shares - and 34 596 085 votes in the company. For further information, please contact: Orexo AB (publ.) Henrik Juuel, EVP and CFO Lena Wange, IR & Communications ManagerTel: +46 (0)18 780 88 00 Tel: +46 (0)18 780 88 00E-mail: ir@orexo.com E-mail:

    Number of shares and votes in Orexo

    Uppsala, Sweden – October 31, 2016 – The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants in connection with the company’s incentive programs and, as previous announced, by issue and repurchase of class C shares. Today, the last trading day of the month, there are in total 34,870,326 shares - whereof 34,535,326 are ordinary shares and 335,000 class C shares - and 34,568,826 votes in the company. For further information, please contact: Orexo AB (publ.) Henrik Juuel, EVP and CFO Lena Wange, IR   & Communications ManagerTel: 018 780

    Number of shares and votes in Orexo

    Uppsala, Sweden – September 30, 2016 – The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants in connection with the company’s incentive programs. Today, the last trading day of the month, there are in total 34,666,107 shares - whereof 34,531,107 are ordinary shares and 135,000 class C shares - and 34,544,607 votes in the company. For further information, please contact: Orexo AB (publ.) Henrik Juuel, EVP and CFO Lena Wange, IR & Communications ManagerTel: 018 780 88 00 Tel: 018 780 88 00email: ir@orexo.com email:

    Number of shares and votes in Orexo

    Uppsala, Sweden – February 29, 2016 – The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants in connection with the company’s incentive programs. Today, the last trading day of the month, there are in total 34,583,763 shares - whereof 34,448,763 are ordinary shares and 135,000 class C shares - and 34,462,263 votes in the company. For further information, please contact:Henrik Juuel, EVP and Chief Financial OfficerTel: +46 (0)18-780 88 00, E-mail: ir@orexo.com About OrexoOrexo is a specialty pharmaceutical company commercializing its

    Number of shares and votes in Orexo

    Uppsala, Sweden – July 31, 2015 – The number of shares and votes in Orexo AB have changed as a result of that the company has repurchased the entire issue of class C shares. Today, the last trading day of the month, there are in total 34,580,810 shares - whereof 34,445,810 are ordinary shares and 135,000 class C shares - and 34,459,310 votes in the company. For further information, please contact:Henrik Juuel, EVP and Chief Financial OfficerTel: +46 (0)18-780 88 00, E-mail: ir@orexo.com About OrexoOrexo is a specialty pharmaceutical company commercializing its proprietary

    Number of shares and votes in Orexo

    Uppsala, Sweden – June 30, 2015 - The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants in connection with the company’s incentive programs. Today, the last trading day of the month, there are in total 34,445,810 shares and votes in the company. For further information, please contact:Henrik Juuel, EVP and Chief Financial OfficerTel: +46 (0)18-780 88 00, E-mail: ir@orexo.com About OrexoOrexo is a specialty pharmaceutical company commercializing its proprietary product Zubsolv® for maintenance treatment of opioid dependence in the US.

    Number of shares and votes in Orexo

    Uppsala, Sweden - May 29, 2015 - The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants in connection with the company’s incentive programs. Today, the last trading day of the month, there are in total 34,399,723 shares and votes in the company. For further information, please contact:Henrik Juuel, EVP and Chief Financial OfficerTel: +46 (0)18-780 88 00, E-mail: ir@orexo.com About OrexoOrexo is a specialty pharmaceutical company commercializing its proprietary product Zubsolv® for maintenance treatment of opioid dependence in the US.

    Number of shares and votes in Orexo

    Uppsala, Sweden – March 31, 2015 - The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants in connection with the company’s incentive programs. Today, the last trading day of the month, there are in total 34,358,897 shares and votes in the company. For further information, please contact:Henrik Juuel, EVP and Chief Financial OfficerTel: +46 (0)18-780 88 00, E-mail: ir@orexo.com About OrexoOrexo is an integrated pharmaceutical company with commercial operations in the United States and R&D in Sweden developing improved treatments using

    Number of shares and votes in Orexo

    Uppsala, Sweden – January 30, 2015 - The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants in connection with the company’s incentive programs. Today, the last trading day of the month, there are in total 34,345,697 shares and votes in the company. For further information, please contact:Henrik Juuel, EVP and Chief Financial OfficerTel: +46 (0)18-780 88 00, E-mail: ir@orexo.com About OrexoOrexo is a specialty pharma company with commercial operations in the United States and R&D in Sweden developing improved treatments using

    Number of shares and votes in Orexo

    Uppsala, Sweden – November 28, 2014 - The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants in connection with the company’s incentive programs. Today, the last trading day of the month, there are in total 34,342,197 shares and votes in the company. For further information, please contact:Henrik Juuel, EVP and Chief Financial OfficerTel: +46 (0)18-780 88 00, E-mail: ir@orexo.com About OrexoOrexo is a specialty pharma company with commercial operations in the United States and R&D in Sweden developing improved treatments using

    Number of shares and votes in Orexo

    Uppsala, Sweden – September 30, 2014 - The number of shares and votes in Orexo has changed as a result of a directed issue of new shares that was resolved on August 28, 2014. Today, the last trading day of the month, there are in total 34,325,155 shares and votes in the company. For further information, please contact:Henrik Juuel, EVP and Chief Financial OfficerTel: +46 (0)18-780 88 00, E-mail: ir@orexo.com About OrexoOrexo is a specialty pharma company with commercial operations in the United States and R&D in Sweden developing improved treatments using proprietary drug

    Number of shares and votes in Orexo

    Uppsala, Sweden – July 31, 2014 - The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants in connection with the company’s incentive programs. Today, the last trading day of the month, there are in total 32,953,233 shares and votes in the company. For further information, please contact:Henrik Juuel, EVP and Chief Financial OfficerTel: +46 (0)18-780 88 00, E-mail: ir@orexo.com About OrexoOrexo is a specialty pharma company with commercial operations in the United States and R&D in Sweden developing improved treatments using proprietary

    Number of shares and votes in Orexo

    Uppsala, Sweden – May 30, 2014 - The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants in connection with the company’s incentive programs. Today, the last trading day of the month, there are in total 32,944,983 shares and votes in the company. For further information, please contact:Henrik Juuel, EVP and Chief Financial OfficerTel: +46 (0)18-780 88 00, E-mail: ir@orexo.com About OrexoOrexo is a specialty pharmaceutical company with commercial operations in the United States and R&D in Sweden developing improved treatments using

    Number of shares and votes in Orexo

    Uppsala, Sweden – March 31, 2014 - The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants in connection with the company’s incentive programs. Today, the last trading day of the month, there are in total 32,938,733 shares and votes in the company. For further information, please contact:Henrik Juuel, EVP and Chief Financial OfficerTel: +46 (0)18-780 88 00, E-mail: ir@orexo.com About Orexo Orexo is a specialty pharmaceutical company with commercial operations in the United States and R&D in Sweden developing improved treatments using

    Number of shares and votes in Orexo

    Uppsala, Sweden – January 31, 2014 - The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants in connection with the company’s incentive programs. Today, the last trading day of the month, there are in total 32,914,908 shares and votes in the company. For further information, please contact:Henrik Juuel, EVP and Chief Financial OfficerTel: +46 (0)18-780 88 00, E-mail: ir@orexo.com About OrexoOrexo is an emerging specialty pharma company with commercial operations in the United States and R&D in Sweden developing improved treatments using

    Number of shares and votes in Orexo

    Uppsala, Sweden – November 29, 2013 - The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants in connection with the company’s incentive programs. Today, the last trading day of the month, there are in total 32,882,408 shares and votes in the company. For further information, please contact:Henrik Juuel, EVP and Chief Financial OfficerTel: +46 (0)722-20 94 77, E-mail: ir@orexo.com About OrexoOrexo is an emerging specialty pharma company with commercial operations in the United States and R&D in Sweden developing improved treatments using

    Number of shares and votes in Orexo

    Uppsala, Sweden – October 31, 2013 - The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants in connection with the company’s incentive programs. Today, the last trading day of the month, there are in total 32,678,941 shares and votes in the company. For further information, please contact:Henrik Juuel, EVP and Chief Financial OfficerTel: +46 (0)722-20 94 77, E-mail: henrik.juuel@orexo.com About OrexoOrexo is an emerging specialty pharma company with commercial operations in the United States and R&D in Sweden developing improved

    Number of shares and votes in Orexo

    Uppsala, Sweden – September 30, 2013 - The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants. Today, the last trading day of the month, there are in total 32,674,441 shares and votes in the company. For further information, please contact:Henrik Juuel, EVP and Chief Financial OfficerTel: +46 (0)722-20 94 77, E-mail: henrik.juuel@orexo.com About OrexoOrexo is an emerging specialty pharma company with commercial operations in the United States and R&D in Sweden developing improved treatments using proprietary drug delivery technology and

    Number of shares and votes in Orexo

    Uppsala, Sweden – August 30, 2013 - The number of shares and votes in Orexo AB has changed as a result of the conversion of convertible bonds subscribed for by Novo A/S and the exercise of warrants. Today, the last trading day of the month, there are in total 32,532,858 shares and votes in the company. For further information, please contact:Henrik Juuel, EVP and Chief Financial OfficerTel: +46 (0)722-20 94 77, E-mail: henrik.juuel@orexo.com About OrexoOrexo AB is an emerging specialty pharma company with commercial operations in the United States and R&D in Sweden developing

    Orexo AB converts convertible bonds subscribed for by Novo A/S

    Uppsala, Sweden - August 26, 2013 – During the second quarter of 2010 Novo A/S subscribed for a convertible bond issue of MSEK 111 by Orexo AB. The bonds have a fixed rate coupon of 8 per cent per annum and a conversion price of SEK 47.50. When Orexo AB’s share price exceeds the conversion price by 50% during a certain period, Orexo AB has the right to convert the convertible bonds and accrued interest into shares. The conditions for conversion were met on August 23, 2013 and Orexo AB then resolved to exercise its right to convert. Pursuant to the conditions for the bonds, not only the

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media